{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03850366",
            "orgStudyIdInfo": {
                "id": "10313"
            },
            "organization": {
                "fullName": "Henry Ford Health System",
                "class": "OTHER"
            },
            "briefTitle": "HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib",
            "officialTitle": "HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib Following Fludarbine/Melphalan/Total Body Irradiation Conditioning Regimen",
            "therapeuticArea": [
                "Other"
            ],
            "study": "hla-haploidentical-peripheral-blood-stem-cell-transplantation-with-post-transplant-cyclophosphamide-and-bortezomib"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2016-03-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-01-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-01-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-02-20",
            "studyFirstSubmitQcDate": "2019-02-20",
            "studyFirstPostDateStruct": {
                "date": "2019-02-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Shatha Farhan",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Henry Ford Health System"
            },
            "leadSponsor": {
                "name": "Henry Ford Health System",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can prevent GVHD and help enhance immune reconstitution. this study is to assess the engraftment rate in patients with hematologic malignancies who need allogeneic stem cell transplant but do not have a suitable matched related or unrelated stem cell donor and will get T-cell replete HLA-Haploidentical allogeneic peripheral stem cell transplantation using post transplant Cyclophosphamide and bortezomib"
        },
        "conditionsModule": {
            "conditions": [
                "Hematological Malignancy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 15,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Bortezomib",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Bortezomib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Bortezomib",
                    "description": "GVHD prophylaxis",
                    "armGroupLabels": [
                        "Bortezomib"
                    ],
                    "otherNames": [
                        "cyclophosphamide"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "engraftment rate",
                    "description": "rate of neutrophil and platelet engraftment post stem cell transplant",
                    "timeFrame": "within 30 days post transplant"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* 18-65 years old patient lacking a matched related donor or unrelated donor but have a related haploidentical donor (\\</= 7/8 allele match at the A, B, C, DR loci with a minimum match of 5/10 is required) is identified\n* Candidate for stem cell transplant in a malignant hematological condition\n* Karnofsky Performance Scale 0-1\n* Available donor able to undergo a Peripheral blood stem cells collection\n* Bilirubin \\</= 1.5 mg/dl , aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\</= 200 IU/ml for adults.\n* Serum creatinine clearance \\>/=60 ml/min (calculated with Cockroft-Gault formula)\n* Diffusing capacity for carbon monoxide (DLCO) \\>/= 45% predicted corrected for hemoglobin.\n* Left ventricle ejection fraction \\> 40%.\n* Patient or patient's legal representative, parent(s) or guardian should provide written informed consent.\n\nExclusion Criteria:\n\n* Adult who has a suitable related or unrelated donor or cord units available for transplant. Suitable donors include 8/8 (HLA-A,B,C and DR, with all loci high-resolution typing) or 7/8 related or unrelated donor available within 42 days of search initiation\n* HIV positive; active hepatitis B or C\n* Patients with active uncontrolled infections.\n* Liver cirrhosis\n* Uncontrolled central nervous system involvement by tumor cells\n* Positive Beta Human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.\n* Inability to comply with medical therapy or follow-up",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "shatha farhan",
                    "role": "CONTACT",
                    "phone": "313 713 3910",
                    "email": "sfarhan1@hfhs.org"
                }
            ],
            "locations": [
                {
                    "facility": "Henry Ford hospital",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "shatha farhan",
                            "role": "CONTACT",
                            "phone": "313-916-5002"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematological Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000069286",
                    "term": "Bortezomib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11541",
                    "name": "Melphalan",
                    "relevance": "LOW"
                },
                {
                    "id": "M376",
                    "name": "Bortezomib",
                    "asFound": "Includes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}